Access to healthcare is a fundamental human right, and it is the government’s responsibility to ensure that its citizens receive reliable medical services backed up by a strong healthcare infrastructure. In recent decades, both the government and healthcare sectors have been seeking an effective solution to the rise of counterfeit pharmaceuticals, which pose a major threat to society. According to the World Health Organization's estimates, approximately 40 percent of medicines developed in low-income countries may be adulterated or denatured. Counterfeit drugs lead to economic loss in the billions worldwide, risks to patient safety, and diversion of funds towards pharmaceutical research and innovation. A decade-long strategy has been introduced by the United States Food and Drug Administration as a response to these concerns, the plan aiming to improve drug traceability throughout the supply chain process. The task of mandating the printing of barcodes and human-readable data on packaging has been designated to the Healthcare Distribution Alliance. Moreover, the FDA is also involved in helping wholesalers and pharmaceutical manufacturers to leverage blockchain technology for secure data transfer and traceability within interoperable digital networks. Preventing counterfeit medicines from making their way into the supply chain remains a major obstacle for governments and regulatory authorities. Likewise, there is an increasing emphasis on implementing stricter guidelines to avert counterfeiters and criminals from infiltrating counterfeit medicines into the market. The healthcare sector requires strong regulatory measures and secure technologies to ensure the shipment of safe, authentic drugs to patients.